Search global stocks & ETFs...Ctrl K
Learn Mode
KRYS
Stock Profile
08-03
Recommended Metric
Score Card
Explore Scores Tab
4.05
Good
Valuation Score
Key Score
3.00
Average
Management
5.00
Very Good
Growth
2.00
Bad
Profitability
3.00
Average
Fin. Health
5.00
Very Good
Dividends
--
--
Analyst
4.00
Good
Insider Transactions
Explore Insider Tab ›Buy Transactions
Sell Transactions
Peers
Select stocks to compare
Price Targets & Ratings
View Analysis
1-year price targets, ending May 11, 2027
Current
$371.58
Baseline
High
$418.95
▲
12.75%
Avg
$315.49
▼
-15.10%
Low
$217.15
▼
-41.56%
Analyst Ratings based on 18 Analysts
Strong Buy
739%
Buy
950%
Hold
211%
Sell
000%
Strong Sell
000%
Krystal Biotech, Inc. operates as a biotechnology company, which engages in discovery, development, manufacturing, and commercialization of pharmaceutical products. The company is headquartered in Pittsburgh, Pennsylvania and currently employs 295 full-time employees. The company went IPO on 2017-09-20. The firm is focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs. Its product candidates in various stages of clinical and preclinical development include KB407, KB408, KB707, KB105, KB801, KB803, KB304 and KB301. Its commercial product, VYJUVEK, is a redosable gene therapy, and a genetic medicine approved in the United States and Europe for the treatment of dystrophic epidermolysis bullosa. KB407 is being developed for the treatment of Cystic Fibrosis. KB408 is being developed for the treatment of Alpha-1 Antitrypsin Deficiency, a rare lung disease. KB707 is being developed for the treatment of solid tumors. KB105 is being developed for TGM1-Deficient Autosomal Recessive Congenital Ichthyosis. KB803 is a redosable eye drop formulation of B-VEC, designed for the treatment of ocular complications.Read More